Inovio and VGX to merge
This article was originally published in Scrip
Executive Summary
The US firms Inovio Biomedical, a developer of electroporation-based DNA vaccine delivery technology, and VGX Pharmaceuticals, a privately-held DNA vaccine developer, are to merge in an all-stock transaction expected to close in the fourth quarter.